Presentation TCT 2024 TCT 485: Device-Related Adverse Events and Modes of Failure Related to Renal Denervation Systems: Insights From Analysis of the FDA MAUDE Database Presenter: Manasa Jasti October 28, 2024
Presentation TCT 2024 TCT 484: Twelve Week Safety and Efficacy of a Novel Extravascular Bi-lateral Renal Denervation Device in a Porcine Model at Nominal Dose Presenter: Abraham Tzafriri October 28, 2024
Presentation TCT 2024 TCT 483: One Year Follow-Up Effect of Renal Sympathetic Denervation After Percutaneous Coronary Intervention in Patients With Resistant Hypertension and Type 2 Diabetes Mellitus Presenter: Daria Feshchenko October 28, 2024
Presentation TCT 2024 TCT 482: Anatomical Predictors for Blood Pressure Outcome After Endovascular Ultrasound Renal Denervation Presenter: Karl Fengler October 28, 2024
Presentation TCT 2024 TCT 481: Renal Artery Imaging Through Long-Term Follow-Up Following Radiofrequency Renal Denervation: Results From the SPYRAL Clinical Trial Program Presenter: Felix Mahfoud October 28, 2024
Presentation TCT 2024 TCT 480: Blood Pressure Reductions by Radiofrequency Renal Denervation Procedural Characteristics: Pooled 24-Month Results From the SYMPLICITY Clinical Program Presenter: Felix Mahfoud October 28, 2024
Presentation TCT 2024 The Body of Evidence: Safety, Efficacy and Sustainability of rf RDN Presenter: Felix Mahfoud October 28, 2024
Presentation TCT 2024 Setting the Standard: Patient Selection &the Safe and Effective Use of RDN Presenter: Tai Kobayashi October 28, 2024
Presentation TCT 2024 Hypertension State of Union and Role of RDN Presenter: Roxana Mehran October 28, 2024
News Conference News TCT 2024 Radiation Survey Reveals Variable Practices as Operators Look to Themselves for Fixes L.A. McKeown October 27, 2024
Presentation TCT 2024 Digital Era in Dermatology with Noninvasive Virtual Skin Biopsies (Enspectra Health) (69301) Presenter: Gabriel Sanchez October 27, 2024
Presentation TCT 2024 Too Good to Be True? Five Top Lessons of Major GLP-1 Agonists Trials Presenter: C. Michael Gibson October 27, 2024
Presentation TCT 2024 How Great if True: My Futuristic View in How GLP-1 Agonist Will Continue Expanding Its Therapeutic Reach Presenter: Marc Bonaca October 27, 2024
News Daily News Michelle Tarver Named New FDA Director of Medical Devices L.A. McKeown October 25, 2024
News Daily News SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients L.A. McKeown October 23, 2024
News Daily News Defying Earlier GLP-1 Data, Study in Teens Sees Possible Mental Health Gains L.A. McKeown October 22, 2024